0001140361-18-017371.txt : 20180405
0001140361-18-017371.hdr.sgml : 20180405
20180405112213
ACCESSION NUMBER: 0001140361-18-017371
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20180405
DATE AS OF CHANGE: 20180405
EFFECTIVENESS DATE: 20180405
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eleven Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001485003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262025616
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-309400
FILM NUMBER: 18739715
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-444-8550
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
STREET 2: SUITE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
D
1
primary_doc.xml
X0708
D
LIVE
0001485003
Eleven Biotherapeutics, Inc.
245 FIRST STREET
SUITE 1800
CAMBRIDGE
MA
MASSACHUSETTS
02142
617-444-8550
DELAWARE
None
None
Corporation
true
Stephen
A.
Hurly
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Executive Officer
Director
President and Chief Executive Officer
Richard
F.
Fitzgerald
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Executive Officer
Chief Financial Officer, Secretary and Treasurer
Wendy
L.
Dixon
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Chairman of the Board of Directors
Abbie
C.
Celniker
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Paul
G.
Chaney
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Leslie
Dan
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Jay
S.
Duker
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Barry
J.
Gertz
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Jane
V.
Henderson
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Daniel
S.
Lynch
245 First Street, Suite 1800
Cambridge
MA
MASSACHUSETTS
02142
Director
Biotechnology
Decline to Disclose
- 06b
false
2018-03-21
false
true
true
true
false
0
Laidlaw & Company (UK) Ltd.
119037
None
None
546 Fifth Avenue
New York
NY
NEW YORK
10036
CA
CALIFORNIA
CT
CONNECTICUT
IL
ILLINOIS
MA
MASSACHUSETTS
MD
MARYLAND
NJ
NEW JERSEY
NY
NEW YORK
OR
OREGON
TX
TEXAS
false
996016
996016
0
false
10
36093
30852
The Company agreed to pay H.C. Wainwright & Co., LLC a portion of the fees which would have otherwise been payable to Laidlaw & Company (UK) Ltd., as a finders' fee in connection with the issuance of the securities under the purchase agreement.
0
false
Eleven Biotherapeutics, Inc.
/s/ Stephen A. Hurly
Stephen A. Hurly
President and Chief Executive Officer
2018-04-05